Technology’s Growing Role in Mental Health
Ryan Allway
June 8th, 2020
Exclusive, News, Top Story, Uncategorized
The COVID-19 crisis has had a profound impact on the healthcare system and is likely to create one of the greatest mental health challenges the world has ever seen. While some technologies have been perceived as detrimental to one’s health, such as social media or gaming, others could be the key to addressing the looming mental health crisis.
Let’s take a look at how technology is playing a role in mental health and some unique corners of the market where investors can find opportunities.
Click here to learn more about investing in the MindLeap mental health platform
Quantifying the Problem
It’s important to understand the scope of the world’s mental health crisis before diving into the ways that technology can improve the situation.
Nearly half of adults (46.4%) will experience a mental illness during their lifetime, according to USA Mental Health First Aid, and five percent of adults (43.8 million people) experience a mental illness in any given year in the United States.
Despite the prevalence of mental health disorders, only 41% of people who have a mental disorder in the past year received professional health care or other necessary services. Patients miss roughly 1-in-5 of their scheduled mental health appointments for a variety of reasons and half of those that miss an appointment drop out of care.
Those that seek care from a primary care physician are often prescribed psychotropic medications without being evaluated by a mental health professional. In addition, just one-in-five patients taking anti-depressants received psychotherapy in 2005 compared to one-in-three in 1996—and those figures continue to trend downwards.
Click here to learn more about investing in the MindLeap mental health platform
Enabling Telemedicine
Telemedicine with online video has made it easier for mental health patients to access consistent care. In addition to connecting from home, telemedicine provides instant rebooking, no wait times, easy rescheduling, and improved privacy. It also helps overcome anxiety, depression and other mental health factors affecting appointments.
Patient outcomes from telehealth based on frequency in academic literature.
Source: Mindleap
Despite its strong potential, less than 20% of Americans use telemedicine services—and the same is true across many other geographies. Many patients are skeptical of its reliability and effectiveness, while others prefer to see people in-person. One study found that remote doctors routinely made misdiagnoses and others don’t have licenses in inpatient locations.
The COVID-19 pandemic could change these habits and encourage a secular shift towards telemedicine. Patients that haven’t been able to revive care due to the greater risk of COVID-19 infection have embraced telemedicine as a way to receive opinions and treatment. Telemedicine is even being used as a “forward triage” ahead of certain visits.
Supporting Psychedelics
Psychedelics have shown promise in clinical research on mental health disorders. As dissociative drugs, ketamine, psilocybin and magic mushrooms alter a patient’s perception of space and time and create euphoric and mystical experiences. They also have a good safety profile when looking at mortality, dependence, mental functioning, injury and crime.
Mindleap is an advanced digital health platform that helps people connect with mental health specialists that can empower them to thrive and develop habits for a healthy mind. In addition to tracking moods, emotions and habits, the platform provides integrated coaching to assist people in translating psychedelic experiences into positive change. The company will also be offering addiction and holistic wellness services along with digital programs.
Mindleap’s psychedelic aftercare helps patients process the events, emotions and thoughts that they experience during a trip. These experiences might include things like processing trauma, overcoming fears and anxieties, as well as other forms of self-discovery. Without a telehealth platform, patients using psychedelics are largely on their own.
Looking Ahead
The COVID-19 crisis could have a profound impact on the way that mental health patients access care. With telemedicine, patients can access better care without the barriers that they face when booking physical appointments. Those turning to psychedelic therapies can also access aftercare to help them process through their self-discoveries.
For more information, visit Mindleap’s website at www.mindleap.health.
Click here to learn more about investing in the MindLeap mental health platform
Resources
Disclaimer
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
In addition to his role as Founder and CEO at MAZAKALI, Sumit is a consultant to The Arcview Group and the Managing Partner of Emerald Ventures. A frequent speaker at investment seminars, Sumit acts as a mentor to Arcview and Canopy companies and serves on the Canopy Investment committee as well as the NCIA Finance […]
Matt Hawkins is the founder and managing principal of Cresco Capital Partners, LLC (“Cresco”), a private equity firm focused specifically on investing in the legalized cannabis industry. Since its inception in the summer of 2015, Cresco has made 14 investments out of its first fund and is currently raising this fund, Fund II. Prior to the […]
HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
